Participated · Series A · May 2026

Cytospire Therapeutics develops differentiated multispecific engager antibodies that bind and activate both tissue/tumour and blood-resident gamma delta T cells to direct innate and adaptive effector immune responses. Its core technology aims to enable safer and more efficacious targeting of validated antigens that are intractable to CD3 T cell engagers due to toxicity. The company's lead programme, CYT X300, is in IND-enabling preclinical studies while the firm is advancing GMP manufacturing for the asset. Cytospire plans to use its newly raised Series A proceeds to progress this pipeline work. The company is led by CEO Natalie Mount. Recent corporate developments include strengthening the board with appointments from participating investors following the financing.

Led · Equity · Nov 2025

Founded in 2019 out of research at the Karolinska Institute, BOOST Pharma focuses on novel mesenchymal stem-cell treatments for rare skeletal pediatric diseases, with its lead candidate BT-101 targeting osteogenesis imperfecta. BT-101 is designed for prenatal or early-life administration so the cells migrate to bone, engraft, and reduce fracture frequency by addressing the underlying genetic defect. Pre-clinical mouse studies demonstrated increased calcium deposition, alkaline phosphatase activity, and ectopic bone formation, while a human proof-of-concept in four children with Type III and IV OI showed improved growth curves and markedly fewer fractures without safety issues or immune reactions. The company positions BT-101 as the first disease-modifying therapy for OI, aiming to enhance bone strength and potentially lung function throughout childhood. Current efforts are directed toward advancing BT-101 through clinical development and ultimately to market. Financially, BOOST Pharma has just secured an additional €3.1 million and is backed by a collaborative investor syndicate that now includes Sound Bioventures. The new funds extend the company’s runway to reach upcoming clinical milestones.

Participated · Series B · Sep 2025

ARTHEx Biotech is a clinical-stage company specializing in targeted RNA medicines that precisely modulate gene expression across skeletal muscle, heart and brain tissues. Its lead program, ATX-01, is an oleic-acid-conjugated anti-miR oligonucleotide designed to inhibit microRNA-23b and restore MBNL protein function in myotonic dystrophy type 1 (DM1); the drug is currently being evaluated in the randomized, placebo-controlled Phase I/IIa ArthemiR™ study. ATX-01 has secured Orphan Drug Designation in both the United States and Europe, as well as Rare Pediatric Disease Designation from the FDA. Preclinical data show the therapy increases MBNL production, reduces toxic DMPK mRNA and corrects spliceopathy in animal and cell models. Beyond DM1, ARTHEx is using its delivery platform to build a pipeline for additional muscular, CNS, cardiac and pulmonary diseases with high unmet need. The company’s headquarters are in Valencia, Spain, and it recently upsized its Series B financing to support preparation for a registrational study of ATX-01 and to broaden its pipeline. Including this round, the company has attracted backing from a consortium of European and U.S. life-science investors.

Led · Series A · Jan 2025

AnaCardio is a privately held Swedish clinical-stage biopharmaceutical company founded in 2017 and based on research from Karolinska Institutet. Its lead candidate, AC01, is a first-in-class oral ghrelin receptor agonist designed to enhance cardiac contractility without the adverse effects typical of conventional inotropes. The company reported positive results from an initial study showing safety, target engagement, and improved contractility. Funds from the recent financing will support completion of the phase 1b/2a GOAL-HF1 study, including a 28-day cohort expansion planned for early 2025. Management positions the data and funding as enabling advancement to proof-of-concept and progression toward late-stage clinical development. AnaCardio AB is a Swedish clinical-stage biopharmaceutical company focused on developing novel therapies for heart failure. Its lead asset, AC01, is being developed for patients with heart failure and reduced ejection fraction (HFrEF). The company plans a clinical phase 1b/2a study of AC01 in HFrEF patients, expected to begin at selected centers in several European countries in fall/winter 2022. Proceeds from the recent financing will fund that planned study. AnaCardio was founded on research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. The company frames heart failure as a potentially fatal disease and the most common cause of hospitalization. AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure based on research from Karolinska Institutet. Its lead asset, AC01, targets improved contractility of the heart muscle through a unique and differentiated mechanism. The company completed a fundraising to progress clinical development and is preparing to start a phase 1b/2a study with AC01 in 2022. The new capital enables AnaCardio to complete those preparations and advance its clinical plans. Karolinska Development is a strategic investor and has direct ownership interest amounting to 21 percent. The financing structure and participation signal continued backing from the Nordic life-sciences ecosystem.

Participated · Convertible Note · Aug 2024

Artax Biopharma is a Cambridge, MA-based clinical-stage biotechnology company focused on improving treatment of T cell-driven autoimmune diseases. Its lead asset, AX-158, is the first in a new class of Nck blockers designed to selectively target Nck function and recalibrate T-cell receptor responses. The company’s oral small molecules aim to modulate the immune system without broad immunosuppression, allowing normal immune activation while preventing self-activation. Artax intends to develop its approach both as monotherapy and in combination with other treatments. Results from a Phase 2a clinical trial in psoriasis are expected before year-end. The company is led by CEO Rob Armstrong. Artax Biopharma, led by CEO Joseph Lobacki, is a Cambridge, MA–based clinical-stage biotechnology company focused on developing innovative small molecules that modulate the immune system. Its lead program, AX-158, is a first-in-class oral small-molecule immunomodulating agent in clinical development for T cell–mediated diseases. AX-158 employs a first-in-class mechanism of action that selectively modulates inappropriate T cell activation, with the aim of treating autoimmune and other T cell–mediated disorders without causing immunosuppression. The company is conducting an ongoing Phase 1 trial assessing the safety, exposure, and pharmacokinetics of AX-158 in healthy volunteers and includes ex vivo stimulated measures of pharmacodynamic activity. In preclinical studies AX-158 decreased key cytokines including IFNγ, TNFα, IL-2, IL-1 and IL-6 in whole human blood samples. Artax intends to use the newly raised funds to advance development of AX-158 across its targeted indications. Artax Biopharma, led by CEO Joseph Lobacki, focuses on transforming autoimmune disease treatment through immunomodulation science. The company is developing AX-158, a first-in-class oral small-molecule immunomodulating agent that selectively modulates T cell responses. AX-158 is being pursued as a new way to treat multiple autoimmune diseases without causing the immune suppression commonly associated with current therapies. Proceeds from the recent financing extension will support activities for a planned Q4 2020 Clinical Trial Application (CTA) filing with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for AX-158. The article does not disclose operating metrics such as revenue or user numbers. Artax Biopharma’s lead program is AX-024, an orally dosed, highly selective immunomodulator that inhibits Nck-mediated T-cell receptor signaling. The company has validated the target and mechanism, demonstrated preclinical proof-of-concept across multiple autoimmune and GVHD models, and reported favorable Phase I safety and PK/PD with dose-dependent immunomodulatory effects ex vivo. Artax is developing additional selective Nck inhibitors in partnership with Dr. Balbino Alarcon, whose lab discovered Nck’s role in T-cell activation. The new financing will be used to advance AX-024 through Phase Ib and IIa clinical trials and to further develop the Nck-specific compound portfolio. Artax is headquartered in Cambridge, Massachusetts, and is led by founder and CEO Damia Tormo.